Biosimilar Development
Program
RALEIGH, N.C., April 25, 2012 /PRNewswire-Asia/ --
PRA, a leading Clinical Research Organization, announces a new
agreement with Amgen for a series of Phase III studies to develop
several biosimilar drugs on a worldwide basis. It is intended that
PRA will serve as the sole provider of CRO services for these
studies. A global leader in the biotechnology space, Amgen
conducted a thorough search process to identify a CRO for Amgen's
biosimilar development program and selected PRA. Amgen and PRA
signed the agreement in April 2012.
Under the new agreement, Amgen and PRA will work
together to execute Phase III studies related to Amgen's current
biosimilar portfolio. The agreement is intended to govern the
entire anticipated scope of Amgen's global biosimilar
portfolio.
"This agreement reflects and confirms PRA's
commitment to providing full service support to our clients'
development pipelines," said Kent Thoelke, PRA's Executive Vice
President of Scientific and Medical Affairs. "Our mission is to
assist our clients across all phases of biotech drug development by
combining therapeutic and operational expertise with local
knowledge to help them meet their development goals. As such, this
relationship represents a key milestone in PRA's commitment to
supporting our clients' biosimilar development programs. Amgen is a
blue chip company and a world leader with a global reputation for
excellence in bringing biologic therapies to patients with grievous
illnesses. PRA has a strong track record in executing our clients'
global registration trials and helping to bring new drugs to
market. We are delighted to announce this strategic relationship
with Amgen."
About PRA
PRA is transforming clinical trials through our
people, innovation and transparency. PRA provides personalized
service customized to the unique requirements of each study. We
support our global reach and innovative approach through flexible
and reliable service, delivered by skilled employees dedicated to
ensuring that sponsors achieve their long-term
goals.
We serve our clients across all phases of
pharmaceutical and biotech drug development by combining
therapeutic and operational expertise with local knowledge.
Offering services in 80+ countries and serving sponsors for 30+
years, we have amassed a level of expertise that has enabled us to
work on a variety of compounds, ranging from niche treatments and
therapies to blockbuster drugs. But at PRA, we are looking to the
future, not the past. Our increasingly forward-thinking approach to
transforming the clinical trial landscape will continue to make a
difference to healthcare patients around the
world.
To learn more about PRA, please visit praintl.com,
email [email protected] or call our Global
Headquarters.
SOURCE﹛PRA